Comparison clinical efficacy of nebulized LMWH plus salbotamol in contrast with nebulized salbotamol alone in management of acute asthma attack

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015092215446N4

Enrollment

Registered

2015-10-17

Start date

2015-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Asthma Exacerbation. Asthma

Interventions

Intervention 1: Current Treatments for Control Group: Salbutamole 2.5mg each 20 minutes via nebulizer. Intervention 2: Treatments in Case Group: Salbutamole 2.5mg each 20 minutes via nebulizer KMWH 1m

Treatment - Drugs

Current Treatments for Control Group: Salbutamole 2.5mg each 20 minutes via nebulizer

Treatments in Case Group: Salbutamole 2.5mg each 20 minutes via nebulizer KMWH 1mg/kg each 20 minutes via nebulizer

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Age above 18 years old. 2- Documented Asthmatic Patients with Spiropmetry. Exclusion Criteria: 1- Not response to therapy. 2- Use of epinephrine or MgSO4 or IPPV during treatment. 3- Patient refuse from continue of treament. 4- Lung diseases like ILD. 5- Cigarrete smoking.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Forced Expiratory Volume in First Second (FEV1). Timepoint: Before intervention, 30 minutes after intervention, 60 minutes after intervention, 90 minutes after intervention. Method of measurement: Milliliter with use of Peak Flow Meter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hassan Motamed

Ahvaz University of Medical Sciences

motamed-h@ajums.ac.ir+98 61 3374 3079

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026